Terveystalo (TTALO) Q3 2024 earnings summary

Executive summary

• Achieved strongest Q3 in company history (excluding one COVID-boosted quarter), with significant improvements in profitability and customer satisfaction maintained at all-time highs.

• Strong earnings growth in Q3 2024 driven by improved operational efficiency and robust Healthcare Services performance; profitability target achieved one year ahead of schedule.

• Portfolio Businesses improved profitability despite revenue decline due to contract terminations and consumer headwinds; Swedish business turnaround progressing as planned.

• The company has completed its turnaround phase ahead of schedule and is shifting focus to growth, customer value, and medical quality.

• Healthcare Services segment delivered its sixth consecutive quarter of strong performance, with revenue up 10.8% and adjusted EBITA up 66.6%.

Financial highlights

• Q3 2024 revenue grew to €295.8 million (+5.4% y/y), driven by strong supply, improved sales mix, and early flu season.

• Adjusted EBITDA/EBITA margin reached 12.3% LTM, surpassing the 12% target one year ahead of plan.

• Q3 adjusted EBITA: €34.3m (+62.2% y/y, margin 11.6%); EPS quadrupled to €0.12; net income €14.7m.

• Operating cash flow for Q3 €41.3m (up 16% y/y); LTM operating cash flow €196m.

• Net debt to adjusted EBITDA at 2.3, an all-time low; net debt €545.4m.

Outlook and guidance

• Full-year adjusted EBITDA/EBITA margin guidance narrowed to 12%-12.5%, with scenarios favoring the upper end.

• Q4 expected to be operationally weaker due to one-off labor agreement payments, VAT, and salary increases, but overall performance remains strong.

• Sweden segment revenue expected to decline due to macro weakness; profit improvement program in Sweden on track.

• No material acquisitions or divestments included in outlook; focus shifting to organic growth and investments.